Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Supportive Care in Cancer

• Publication date

  2019-03-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00520-019-04751-yPMID 30919155
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review

  2018cited by this paper
• Vitiligo‐like lesions occurring in patients receiving anti‐programmed cell death–1 therapies are clinically and biologically distinct from vitiligo

  2017cited by this paper
• Anti-PD1/PDL1 induced psoriasis.

  2017cited by this paper
• Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.

  2017cited by this paper
• Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma

  2017cited by this paper
• To Treat or Not to Treat: Role of Immunotherapy in Patients with Concomitant Diagnosis of Advanced-Stage Non-Small Cell Lung Cancer and Psoriasis.

  2017cited by this paper
• Anti‐PD1‐induced psoriasis: a study of 21 patients

  2017cited by this paper
• Dermatological adverse events with taxane chemotherapy

  2016cited by this paper
• Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.

  2016cited by this paper
• Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma.

  2016cited by this paper
• Incidence and implications of chemotherapy related hand-foot syndrome

  2016cited by this paper
• Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.

  2016cited by this paper
• Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma

  2016cited by this paper
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

  2016cited by this paper
• Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

  2016cited by this paper
• Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.

  2016cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

  2015cited by this paper
• The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology.

  2015cited by this paper
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

  2015cited by this paper
• Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

  2012cited by this paper
• The hand‐foot‐syndrome associated with medical tumor therapy – classification and management

  2010cited by this paper
• Prospective Study of Ice Gel Pack as Less Expensive Alternative for Prevention of Skin and Nail Toxicity in Patients with Breast Cancer Receiving Docetaxel.

  2009cited by this paper
• Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis

  2008cited by this paper
• Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.

  2007cited by this paper
• Managing taxane toxicities

  2003cited by this paper
• A CRITICAL REVIEW

  1939cited by this paper

• Acneiform drug eruptions—update on pathophysiology and culprit drugs

  2026cites this paper
• Active monitoring vs. spontaneous reporting of antineoplastic drug–related adverse drug reactions: evidence from the Chinese hospital pharmacovigilance system

  2026cites this paper
• Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice

  2024cites this paper
• Characterization of the role of Facebook groups for patients who use scalp cooling therapy: a survey study

  2024cites this paper
• Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review

  2023cites this paper
• Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer

  2023cites this paper
• Oral Toxicities in Cancer Patients, Who Receive Immunotherapy: A Case Series of 24 Patients

  2023cites this paper
• Immune checkpoint inhibitor-induced cutaneous toxicities: A review of histopathologic and clinical features.

  2023cites this paper
• Evaluation of chemotherapy‐induced cutaneous side effects in cancer patients

  2022cites this paper
• Global research trends on precision cancer medicine-related rashes (2008-2021): A bibliographic study

  2022cites this paper
• Supportive oncodermatology—a narrative review of its utility and the way forward

  2021cites this paper
• Subjective evaluation of skin toxicity and quality of life in patients undergoing anti-cancer treatment at the Department of Cancer Chemotherapy

  2021cites this paper
• Antineoplastics

  2020cites this paper
• Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study

  2019cites this paper